Sun Pharmaceutical Industries Ltd.
https://www.sunpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sun Pharmaceutical Industries Ltd.
EMA Says Yes To BMS’ Sotyktu But Turns Down Ipsen’s Sohonos
The European Medicines Agency has recommended pan-EU marketing approval for four medicines but turned down Ipsen’s treatment for an ultra-rare bone disorder. It has also OK’d new uses of seven already-approved drugs and is reviewing efficacy concerns regarding Novartis’ sickle cell medicine.
Five Big Pharma Products That Saw Action In India; There’s More To Come
Scrip spotlights the action around five key big pharma products in India. We track the gains made by Rybelsus and Keytruda, the wave of Januvia and Ibrance generics and on-market and court action for blockbuster Entresto.
Ibrance Generics Arrive In India, Patient Programs Add Free Drug Component
Pfizer’s Ibrance is set to lose exclusivity in the US only by 2027, but the Indian market is buzzing with activity as generics including from top-ranked drug maker Sun Pharma vie for a share of the pie. Competing CDK4/6 inhibitors are already available but can cut-price palbociclib versions alter market dynamics?
India M&As Overtook PE Activity In 2022, Deal Momentum To Continue In 2023
India had a busy deals calendar in 2022, with companies led by Biocon striking large M&A deals while PE activity declined. Scrip pieced together data for infographics on these deals. A multitude of factors is expected to keep the momentum going in 2023
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Aditya Acquisition Company ltd
- Caraco Pharmaceutical Laboratories, Ltd.
- DUSA Pharmaceuticals, Inc.
- InSite Vision, Inc.
- JSC Biosintez
- Ocular Technologies
- Pola Pharma Inc.
- Ranbaxy Laboratories Limited
- Ranbaxy Solus
- Solus Care
- Sun Ophthalmics
- Sun Pharma Global FZE
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice